We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Patient-reported Outcomes in the Treatment of Schizophrenia

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00230828
Recruitment Status : Completed
First Posted : October 3, 2005
Last Update Posted : September 12, 2013
Information provided by:

Study Description
Brief Summary:
Patient-reported health economic outcomes for patients enrolled in S1543003 and S1543004 protocols

Condition or disease Intervention/treatment Phase
Schizophrenia Drug: bifeprunox Phase 3

Study Design

Study Type : Interventional  (Clinical Trial)
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Treatment
Official Title: Patient-reported Outcomes With Bifeprunox or Olanzapine in the Treatment of Schizophrenia. A Pharmacoeconomic Study Carried Out in Connection With the S1543003 And S1543004 Clinical Trials
Study Start Date : May 2005
Primary Completion Date : January 2006

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Schizophrenia
U.S. FDA Resources

Arms and Interventions

Outcome Measures

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 75 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Participate in S1543003 and S1543004 in the U.S. sites

Exclusion Criteria:

  • Participate in S1543003 and S1543004 other than U.S. sites
Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00230828

Sponsors and Collaborators
Solvay Pharmaceuticals
Study Director: Global Clinical Director Solvay Solvay Pharmaceuticals
More Information

ClinicalTrials.gov Identifier: NCT00230828     History of Changes
Other Study ID Numbers: S154.3.005
First Posted: October 3, 2005    Key Record Dates
Last Update Posted: September 12, 2013
Last Verified: September 2007

Additional relevant MeSH terms:
Schizophrenia Spectrum and Other Psychotic Disorders
Mental Disorders